BEIJING - Tasly Pharmaceutical Group Co Ltd, a leading pharmaceutical company in China, said Saturday that its net profit in the first half of the year rose 24.04 percent year on year to 744.5 million yuan ($120.9 million).
Business revenues rose 13.07 percent from a year earlier to 6.1 billion yuan, according to the company's interim report.
Earning per share for the period stood at 0.72 yuan.
Tasly is one of China's largest producers of traditional Chinese medicines. Its business scope also includes chemical and biological drugs, healthcare products, and functional foods.
 |
 |
| Pharmaceutical sector ripe for innovation |
|
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263 Registration Number: 20100000002731 
